Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-11-02 Report Publication Anno…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "Press Release 2 November 2016" and its primary purpose is to announce *when* the Q3 2016 results will be released ("Results to be announced on 8 November 2016") and to provide details for the subsequent conference call (dial-in numbers, time). This is not the full Earnings Release (ER) itself, nor is it the comprehensive Interim Report (IR). It is an announcement *about* the upcoming release of financial results and the associated call. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2016-11-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and explicitly states: "Bone Therapeutics publiera son rapport d'activité du T3 2016, le 8 novembre 2016" (Bone Therapeutics will publish its Q3 2016 activity report on November 8, 2016). This document is an announcement about the future release of a periodic financial report (Q3 activity report), not the report itself. According to Rule 2, when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). The content details the date/time of the report release and the subsequent conference call details, confirming its nature as an announcement.
2016-11-02 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the CEO, Enrico Bastianelli, is stepping down, and Thomas Lienard is appointed Interim CEO. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The text is clearly an announcement, not a full financial report or transcript.
2016-10-11 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is titled "Information réglementée/privilégiée" (Regulated/Privileged Information) and announces that the CEO, Enrico Bastianelli, is leaving his position, with the Chief Business Officer, Thomas Lienard, taking over as interim CEO. This clearly falls under the category of announcing changes in senior management or the board of directors. This matches the definition for Board/Management Information (MANG). The document is a formal announcement, not a transcript, financial report, or proxy statement.
2016-10-11 French
Enrico Bastianelli to stand down as CEO of Bone Therapeutics
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the CEO, Enrico Bastianelli, is stepping down, and Thomas Lienard is appointed Interim CEO. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The text is clearly an announcement, not a full financial report or transcript.
2016-10-11 English
Enrico Bastianelli quitte ses fonctions de Directeur Général de Bone Therapeutics
Board/Management Information Classification · 99% confidence The document is titled "Information réglementée/privilégiée" (Regulated/Privileged Information) and announces that the CEO, Enrico Bastianelli, is leaving his position, with the Chief Business Officer, Thomas Lienard, taking over as interim CEO. This clearly falls under the category of announcing changes in senior management or the board of directors. This matches the definition for Board/Management Information (MANG). The document is a formal announcement, not a transcript, financial report, or proxy statement.
2016-10-11 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.